Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Pathologically confirmed adenocarcinoma of the pancreas

• Patient have undergone a potentially curative resection

• No previous irradiation to the planned field

• Negative pregnancy test for child bearing women

Exclusion Criteria:

• Non-adenocarcinoma pancreatic cancer

• Treatment with any drug within the last 30 days that has not received regulatory approval.

• Serious systemic disorder

• Metastatic disease

• Pregnancy, breast feeding